ArticleGenes, chromosomes & cancer2009
Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy.
Article in Genes, chromosomes & cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 229 citations in OpenAlex.
- Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer.Medical oncology (Northwood, London, England) · 2014Trial
- Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.Cancer prevention research (Philadelphia, Pa.) · 2013Trial
- MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion.The Journal of biological chemistry · 2012Trial
- Salivary miRNAs along with p53 and EGFR in oral exfoliated cells: a pilot study on candidate noninvasive biomarkers for the early detection of oral cancer in tobacco users.Molecular biology reports · 2026Article
- Fibroblast growth factor receptor signaling in head and neck tumors: molecular pathogenesis and potential therapeutic targets.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).International journal of molecular medicine · 2025Review
- EBV-Induced LINC00944: A Driver of Oral Cancer Progression and Influencer of Macrophage Differentiation.Cancers · 2025Article
- Overexpression of ORAOV1 and its association with immunotherapy resistance in hepatocellular carcinoma.PeerJ · 2025Article
- The Oncogenic Role ofInternational journal of molecular sciences · 2024Article
- Molecular and Therapeutic Roles of Non-Coding RNAs in Oral Cancer-A Review.Molecules (Basel, Switzerland) · 2024Review
- Applying Machine Learning for Enhanced MicroRNA Analysis: A Companion Risk Tool for Oral Squamous Cell Carcinoma in Standard Care Incisional Biopsy.Biomolecules · 2024Article
- HetFCM: functional co-module discovery by heterogeneous network co-clustering.Nucleic acids research · 2024Article
- Review
- miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023Review
- Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.International journal of molecular sciences · 2022Review
- CircCASC15-miR-100-mTOR may influence the cervical cancer radioresistance.Cancer cell international · 2022Article
- Salivary miR-31-5p, miR-345-3p, and miR-424-3p Are Reliable Biomarkers in Patients with Oral Squamous Cell Carcinoma.Pathogens (Basel, Switzerland) · 2022Article
- The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p.Biomedicines · 2022Article
- Review
- Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma.Cells · 2021Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Altered microRNA (miRNA) expression profiles have been observed in numerous malignancies, including oral squamous cell carcinoma (OSCC). However, their role in disease is not entirely clear. Several genetic aberrations are characteristic of OSCC, with amplification of chromosomal band 11q13 and loss of distal 11q being among the most prevalent. It is not known if the expression levels of miRNAs in these regions are altered or whether they play a role in disease. We hypothesize that the expression of miRNAs mapping to 11q are altered in OSCC because of loss or amplification of chromosomal material, and that this contributes to the development and progression of OSCC. We found that miR-125b and miR-100 are down-regulated in OSCC tumor and cell lines, and that transfecting cells with exogenous miR-125b and miR-100 significantly reduced cell proliferation and modified the expression of target and nontarget genes, including some that are overexpressed in radioresistant OSCC cells. In conclusion, the down-regulation of miR-125b and miR-100 in OSCC appears to play an important role in the development and/or progression of disease and may contribute to the loss of sensitivity to ionizing radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.